Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Promethera

- PMLiVE

Gilead expands liver disease pipeline with $4.3bn CymaBay acquisition

The deal gives the company access to a candidate being evaluated in primary biliary cholangitis

- PMLiVE

Boehringer Ingelheim and Ribo announce liver disease partnership worth over $2bn

More than 440 million people worldwide are estimated to live with the inflammatory liver disease NASH

- PMLiVE

Gilead’s Veklury recommended by CHMP for COVID-19 in patients with hepatic impairment

If approved, Veklury would become the first COVID-19 antiviral authorised for use across all stages of liver disease

- PMLiVE

Ipsen to acquire rare disease specialist Albireo in deal worth over $950m

The deal will strengthen the biopharma’s liver disease pipeline with the addition of Bylvay

- PMLiVE

Zydus Cadila scores first ever NASH approval, in India

Drug has already been approved for diabetes related conditions

- PMLiVE

Boehringer bolsters NASH pipeline with $870m Yuhan deal

Strengthens existing relationship

- PMLiVE

Promethera’s liver failure stem cell therapy clears first hurdle

Technique could be alternative to transplant

- PMLiVE

Gilead NASH drug clears mid-stage trial, but rivals are looming

Positive results to challenge Intercept in emerging disease area

Bristol-Myers Squibb (BMS) building

BMS claims a win in mid-stage NASH trial

Its new liver disease therapy reduces fatty deposits and improves blood lipid profiles

Novartis day

Novartis buys two firms in pre-Christmas shopping spree

Acquires eye disease specialist Encore Vision and NASH drug firm Conatus Pharma

- PMLiVE

Intercept gets EU nod for rare liver disease therapy

Ocaliva approved as a combination treatment for primary biliary cholangitis

- PMLiVE

Gilead chalks up trial success for new NASH drug

Phase II selonsertib data encouraging for liver disease with no approved therapies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links